Burning Rock Biotech (NASDAQ:BNR) Trading Down 13.4% – Time to Sell?

Burning Rock Biotech Limited (NASDAQ:BNR) shares were down 13.4% during mid-day trading on Monday . The stock traded as low as $4.90 and last traded at $4.90. Approximately 7,883 shares traded hands during mid-day trading, a decline of 43% from the average daily volume of 13,817 shares. The stock had previously closed at $5.66.

Burning Rock Biotech Price Performance

The company’s 50-day moving average is $6.60 and its 200-day moving average is $5.27. The firm has a market capitalization of $50.20 million, a price-to-earnings ratio of -1.63 and a beta of 0.55.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Burning Rock Biotech stock. Citadel Advisors LLC bought a new stake in Burning Rock Biotech Limited (NASDAQ:BNR) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 12,267 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.12% of Burning Rock Biotech as of its most recent filing with the SEC. 30.03% of the stock is owned by hedge funds and other institutional investors.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.